RT @Nader_Guilherme: Paclitaxel-trastuzumab is widely accepted as standard adjuvant Tx for node-neg, HER2+ breast cancer Check out our st…
4,030 followers
71 followers
RT @PTarantinoMD: Nice real-world analysis confirming the outstanding outcomes found in the #APT trial with the TH regimen for stage I HER2…
116 followers
RT @Nader_Guilherme: Paclitaxel-trastuzumab is widely accepted as standard adjuvant Tx for node-neg, HER2+ breast cancer Check out our st…
100 followers
RT @ElisaAgostinett: Now out in @CHematology our real-world🌍 analysis of clinical outcomes of pts with stage1️⃣ HER2+ #breastcancer, led by…